Joshua StoikosWestern University | UWO · Faculty of Health Sciences
Joshua Stoikos
Master of Science
About
10
Publications
680
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
50
Citations
Introduction
Joshua is a third-year PhD Candidate in Western University's combined program pursuing a Master of Physiotherapy (MPT) and PhD in Health and Rehabilitation Sciences. He is supervised by Dr Janelle Unger. Joshua received his Honors Bachelor of Kinesiology and Master of Science degree in Applied Health Sciences from Brock University. His current and past research focuses on elucidating the micro and macro effects of exercise on health.
Skills and Expertise
Publications
Publications (10)
Introduction
Individuals with neurological conditions (e.g., stroke, spinal cord injury, multiple sclerosis) may experience challenges to their mobility. While the individual needs for persons with neurological conditions may vary, thus making intervention development more difficult, identifying key personalization or tailoring variables may help t...
Background
The foremost reported unmet health need for Canadians with chronic neurological conditions is linked to physical maintenance. One way to address this issue is through activity programing offered through public institutions, where rehabilitation can be integrated into secondary health care settings. Parkwood Institute in London, Ontario h...
Sclerostin, a potent inhibitor of the Wnt signaling pathway, plays a critical role in bone homeostasis. Evidence suggests that sclerostin may also be involved in crosstalk between other tissues, including muscle. This pilot study attempted to examine the effects of sclerostin on soleus and extensor digitorum longus (EDL) muscle tissue from male mic...
Sclerostin is an inhibitor of the osteogenic Wnt/β-catenin signalling pathway that has an endocrine role in regulating adipocyte differentiation and metabolism. Additionally, subcutaneous white adipose tissue (scWAT) sclerostin content decreases following exercise training (EXT). Therefore, we hypothesized that EXT-induced reductions in adipose tis...
Introduction: It is well established that sclerostin antagonizes the anabolic Wnt signalling pathway in bone, however, its physiological role in other tissues remains less clear. This study examined the effect of a high-fat diet (HFD) on sclerostin content and downstream markers of the Wnt signaling pathway (GSK3β and β-catenin) within subcutaneous...
This study examined differences in resting concentrations of markers of bone formation and resorption, and osteokines between female adolescent (12–16 y) swimmers, soccer players, and nonathletic controls. Resting, morning blood samples were obtained after an overnight fast from 20 swimmers, 20 soccer players, and 20 nonathletic controls, matched f...
Sclerostin is an inhibitor of the osteogenic Wnt/β-catenin signalling pathway that has an endocrine role in regulating adipocyte differentiation and metabolism. Additionally, subcutaneous white adipose tissue (scWAT) sclerostin content decreases following exercise training (EXT). Therefore, we hypothesized that EXT-induced reductions in adipose tis...
Sclerostin is a Wnt/β-catenin antagonist, mainly secreted by osteocytes, and most known for its role in reducing bone formation. Studies in rodents suggest sclerostin can also regulate adipose tissue mass and metabolism, representing bone-adipose tissue crosstalk. Exercise training has been shown to reduce plasma sclerostin levels; but the effects...
: Glycogen synthase kinase 3 (GSK3) slows myogenic differentiation and myoblast fusion partly by inhibiting the Wnt/β-catenin signaling pathway. Lithium, a common medication for bipolar disorder, inhibits GSK3 via Mg+ competition and increased Ser21 (GSK3α) or Ser9 (GSK3β) phosphorylation, leading to enhanced myoblast fusion and myogenic differenti...